Fruquintinib combined with sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): A phase II, single-arm, prospective study.

被引：0
|
作者：
Jin, Min [1 ]
Yang, Shengli [1 ]
Liu, Junli [1 ]
Zhang, Jieying [1 ]
Zhao, Lei [1 ]
Yu, Dandan [1 ]
Lin, Zhenyu [1 ]
Li, Pindong [1 ]
Wang, Jing [1 ]
Xue, Jun [1 ]
Ma, Hong [1 ]
Hu, Jianli [1 ]
Zhang, Tao [1 ]
Liu, Hongli [1 ]
机构：
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Hubei, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
3282-3306-3348-4026; 261-492-3532-2370-7650-2700; 130-540-543-12277-2683; 613-135-244-3829; 261-492-3532-2370-5109; 613-225-3248-9559-9794-11285; 4; 3; 2; 2461; 2444; 1704; 5; 38116-38094-8;
D O I：
10.1200/JCO.2024.42.3_suppl.332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：332 / 332
页数：1
相关论文
共 50 条
  • [41] Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Li, N.
    Li, Z.
    Fu, Q.
    Zhang, B.
    Zhang, J.
    Wan, X.
    Lu, C.
    Wang, J.
    Deng, W.
    Wei, C.
    Ma, Y.
    Bie, L.
    Wang, M.
    Luo, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1302 - S1302
  • [42] Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.
    Ohtsu, Atsushi
    Tabernero, Josep
    Bang, Yung-Jue
    Fuchs, Charles S.
    Sun, Linda
    Wang, Zhen
    Csiki, Ildiko
    Koshiji, Minori
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [43] Fruquintinib combined with PD-1 inhibitors and chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (FDZL-FIX): A single-arm, open-label phase 2 study.
    Wang, Chenchen
    Huang, Mingzhu
    Dai, Yuedi
    Feng, Wanjing
    Zhao, Xiaoying
    Zhu, Xiaodong
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 461 - 461
  • [44] SOX combined with tislelizumab and low-dose radiation therapy for the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase Ib/II clinical trial
    Zhang, Peng-Fei
    Chen, Ye
    Li, Wen-Ke
    Luo, Zhu-Mei
    Chen, Ji
    Qian, Kun
    Chen, Xiao-Dong
    Wang, Mo-Jin
    Liu, Ming
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [45] Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial
    Wei, Jia
    Lu, Xiaofeng
    Liu, Qin
    Fu, Yao
    Liu, Song
    Li, Lin
    Liu, Fangcen
    Fan, Xiangshan
    Yang, Ju
    Yang, Yang
    Zhao, Yang
    Guan, Wenxian
    Liu, Baorui
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2007 - 2015
  • [46] Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial
    Jinming Shi
    Ning Li
    Yuan Tang
    Liming Jiang
    Lin Yang
    Shulian Wang
    Yongwen Song
    Yueping Liu
    Hui Fang
    Ningning Lu
    Shunan Qi
    Bo Chen
    Ziyu Li
    Shixin Liu
    Jun Wang
    Wenling Wang
    Suyu Zhu
    Jialin Yang
    Yexiong Li
    Dongbing Zhao
    Jing Jin
    BMC Gastroenterology, 22
  • [47] Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial
    Shi, Jinming
    Li, Ning
    Tang, Yuan
    Jiang, Liming
    Yang, Lin
    Wang, Shulian
    Song, Yongwen
    Liu, Yueping
    Fang, Hui
    Lu, Ningning
    Qi, Shunan
    Chen, Bo
    Li, Ziyu
    Liu, Shixin
    Wang, Jun
    Wang, Wenling
    Zhu, Suyu
    Yang, Jialin
    Li, Yexiong
    Zhao, Dongbing
    Jin, Jing
    BMC GASTROENTEROLOGY, 2022, 22 (01)
  • [48] Clinical effectiveness and toxicity of second-line irinotecan in advanced gastric and gastroesophageal junction adenocarcinoma: a single-center observational study
    Ochenduszko, Sebastian
    Puskulluoglu, Miroslawa
    Konopka, Kamil
    Fijorek, Kamil
    Slowik, Agnieszka Julia
    Pedziwiatr, Michal
    Budzynski, Andrzej
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (04) : 223 - 233
  • [49] The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
    Wang, Jianzheng
    He, Yunduan
    Zhang, Baiwen
    Lv, Huifang
    Nie, Caiyun
    Chen, Beibei
    Xu, Weifeng
    Zhao, Jing
    Cheng, Xiaojiao
    Li, Qingli
    Tu, Shuiping
    Chen, Xiaobing
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [50] Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
    Qu, Jinglei
    He, Xin
    Luo, Ying
    Yu, Ping
    Chen, Ying
    Liu, Jing
    Wang, Xin
    Wang, Chang
    Liang, Tingting
    Bai, Yuxian
    Han, Yu
    Man, Li
    Leng, Chuanchun
    Zhou, Caiyun
    He, Lijie
    Liu, Yunpeng
    Qu, Xiujuan
    FRONTIERS IN ONCOLOGY, 2023, 13
12345